RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis
This will address the large unmet need on a global scale for Myasthenia Gravis. RemeGen Co., Ltd., a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA)...